{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:02:47Z","timestamp":1793689367466,"version":"4.5.1"},"reference-count":26,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.yebeh.2014.03.013","type":"journal-article","created":{"date-parts":[[2014,4,27]],"date-time":"2014-04-27T09:45:45Z","timestamp":1398591945000},"page":"6-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["The practical impact of altered dosing on perampanel plasma concentrations: Pharmacokinetic modeling from clinical studies"],"prefix":"10.1016","volume":"35","author":[{"given":"Barry E.","family":"Gidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oneeb","family":"Majid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Laurenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2014.03.013_bb0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.seizure.2010.10.027","article-title":"Antiepileptic drug therapy the story so far","volume":"19","author":"Brodie","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2014.03.013_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2007.00992.x","article-title":"Refractory epilepsy: clinical overview","volume":"248","author":"French","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.yebeh.2008.12.006","article-title":"Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy","volume":"14","author":"Manjunath","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0025","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1528-1167.2007.01414.x","article-title":"Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population","volume":"49","author":"Davis","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1528-1167.2008.01794.x","article-title":"Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study","volume":"50","author":"Faught","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0035","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","article-title":"Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study","volume":"71","author":"Faught","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0040","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0045","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1528-1157.1995.tb00469.x","article-title":"Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial","volume":"36","author":"Cramer","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0050","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/596482","article-title":"Better adherence with once-daily antiretroviral regimens: a meta-analysis","volume":"48","author":"Parienti","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0055","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40271-013-0020-5","article-title":"Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism","volume":"6","author":"Lalibert\u00e9","year":"2013","journal-title":"Patient"},{"key":"10.1016\/j.yebeh.2014.03.013_bb9000","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0065","series-title":"Fycompa [summary of product characteristics]","year":"2012"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0070","series-title":"Fycompa [prescribing information]","year":"2012"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0075","series-title":"Fycompa [product monograph]","year":"2013"},{"issue":"Suppl. 11","key":"10.1016\/j.yebeh.2014.03.013_bb0080","first-page":"98","article-title":"Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist [abstract 1.199]","volume":"50","author":"Templeton","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0085","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14656566.2013.754883","article-title":"Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures","volume":"14","author":"Rektor","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0090","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0095","series-title":"Poster presented at: 65th American Epilepsy Society Annual Meeting; Baltimore, MD, USA","article-title":"Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials","author":"Laurenza","year":"2011"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0100","series-title":"Poster presented at: 66th American Epilepsy Society Annual Meeting; San Diego, CA, USA","article-title":"Impact of delayed dose or missed dose on perampanel plasma concentrations","author":"Gidal","year":"2012"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2014.03.013_bb0105","article-title":"Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures","volume":"11","author":"Fuseau","year":"2011","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0110","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.yebeh.2012.08.027","article-title":"Adherence to antiepilepsy drug therapy","volume":"25","author":"Faught","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.yebeh.2004.01.009","article-title":"Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy","volume":"5","author":"Pellock","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/dkn187","article-title":"Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing","volume":"62","author":"Dickinson","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.yebeh.2014.03.013_bb0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/epi.12043","article-title":"Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations","volume":"54","author":"Leppik","year":"2013","journal-title":"Epilepsia"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505014000948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505014000948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T11:51:11Z","timestamp":1538653871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505014000948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":26,"alternative-id":["S1525505014000948"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2014.03.013","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The practical impact of altered dosing on perampanel plasma concentrations: Pharmacokinetic modeling from clinical studies","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2014.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}